INCY logo

Incyte Corporation (INCY)

$119.09

Quotes are delayed by 15 minutes.

1D

1W

1M

3M

6M

YTD

1Y

2Y

5Y

ALL

Key data on INCY

Market cap

$24.27B

EPS

1.88

P/E ratio

14.3

Price to sales

3.93

Dividend yield

--

Beta

0.782018

Price on INCY

Previous close

$120.27

Today's open

$119.48

Day's range

$118.05 - $121.43

52 week range

$89.25 - $132.60

Profile about INCY

CEO

William J. Meur

Employees

2844

Headquarters

Wilmington, DE

Exchange

Nasdaq Global Select

Shares outstanding

203832492

Issue type

Common Stock

INCY industries and sectors

Healthcare

Biotechnology & Life Sciences

News on INCY

Incyte Corporation (INCY) Presents at Jefferies Global Healthcare Conference 2026 Transcript

Incyte Corporation (INCY) Presents at Jefferies Global Healthcare Conference 2026 Transcript

news source

Seeking Alpha • Nov 17, 2026

news preview

Incyte Corporation (INCY) Presents at UBS Global Biopharma Conference 2026 Transcript

Incyte Corporation (INCY) Presents at UBS Global Biopharma Conference 2026 Transcript

news source

Seeking Alpha • Nov 17, 2026

news preview

INCY Wins European Commission Nod For Skin Disease Drug

Incyte secures EC approval for Povofortay, the first once-daily oral HS treatment in the EU, opening a new growth opportunity backed by strong clinical results.

news source

Zacks Investment Research • Nov 17, 2026

news preview

Incyte says EU approves oral treatment for chronic skin disease

Incyte said on Monday the European Commission had approved its once-daily oral therapy for ​a type of chronic skin disease.

news source

Reuters • Nov 16, 2026

news preview

Povofortay® (povorcitinib) Approved in Europe as the First Once-Daily Oral Treatment for Adults with Moderate to Severe Hidradenitis Suppurativa

WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY--Povofortay® (povorcitinib) Approved in Europe as the First Once-Daily Oral Treatment for Adults with Moderate to Severe Hidradenitis Suppurativa.

news source

Business Wire • Nov 16, 2026

news preview

Incyte Maps Post-Jakafi Growth, Targeting Up to $4 Billion in Other Sales by 2030

Incyte NASDAQ: INCY is preparing for a transition away from its JAKAFI business, with Chief Executive Officer Bill Meury pointing to product launches and a pipeline of late-stage drug candidates as potential sources of growth after 2029.

news source

MarketBeat • Nov 11, 2026

news preview

Incyte Corporation (INCY) Presents at 8th Annual Wolfe Research Healthcare Conference Transcript

Incyte Corporation (INCY) Presents at 8th Annual Wolfe Research Healthcare Conference Transcript

news source

Seeking Alpha • Nov 10, 2026

news preview

Natera Announces Clinical Collaboration with Incyte on Interventional Phase II Study in Colorectal Cancer

AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (Nasdaq:NTRA), a global leader in cell-free DNA and precision medicine, today announced that it has entered into a clinical collaboration agreement with Incyte (Nasdaq:INCY) for a new phase II study in colorectal cancer (CRC). The trial will evaluate INCA33890, Incyte's investigational bispecific immunotherapy, in patients with stage 2/3 CRC who have completed surgery and adjuvant chemotherapy (ACT), incorporating Signatera as both a primary and seco.

news source

Business Wire • Nov 10, 2026

news preview

2026 Incyte Ingenuity Awards in GVHD™ Awarded to University of Maryland School of Medicine and H. Lee Moffitt Cancer Center & Research Institute

WILMINGTON, Del.--(BUSINESS WIRE)--Incyte is proud to announce that the University of Maryland School of Medicine and H. Lee Moffitt Cancer Center & Research Institute have been selected as the recipients of the 2026 Incyte Ingenuity Awards in GVHD™. This annual award program recognizes and supports innovative projects that address the specific needs of individuals impacted by graft-versus-host disease (GVHD), including patients, caregivers and healthcare providers. “It is our honor to reco.

news source

Business Wire • Nov 6, 2026

news preview

Incyte to Present at Upcoming Investor Conferences

WILMINGTON, Del.--(BUSINESS WIRE)--Incyte (Nasdaq:INCY) announced today that it will present at the following investor conferences during the month of November: Wolfe Research Healthcare Conference on Tuesday, November 10, 2026 at 10:00 am (EST) Jefferies Global Healthcare Conference on Tuesday, November 17, 2026 at 9:00 am (GMT) UBS Global Biopharma Conference on Tuesday, November 17, 2026 at 1:20 pm (GMT) The presentations will be webcast live and can be accessed at Investor.Incyte.com and wi.

news source

Business Wire • Nov 4, 2026

news preview

¹ Disclosures

Get started with M1

Invest in Incyte Corporation

Open an M1 investment account to buy and sell Incyte Corporation commission-free¹. Build wealth for the long term using automated trading and transfers.

Invest in INCY on M1